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ORIGINAL RESEARCH
Objectives: Inflammation is known to be a major determinant of the progression of coronary
artery disease (CAD). In the present study we have evaluated the plasma levels of cytokines –
tumor necrosis factor-α (TNF), interleukin-1α (IL-1), interleukin-6 (IL-6), interferon-γ (IFN),
and interleukin-10 (IL-10) – to examine the association between these cytokines and C-reactive
protein (CRP) in patients with CAD.
Methods: Patients with acute coronary syndromes (ACS; n = 20) were compared with patients
with stable angina (SA; n = 20) and with control volunteers (C; n = 20). Blood samples were
collected at the time of admission from all patients and 15 and 30 days thereafter.
Results: CRP levels (20.8 ± 8.8 mg/L) (mean ± SEM) were higher at baseline in ACS than SA
patients (4.1 ± 0.8 mg/L) or the control subjects (5.1 ± 1.8 mg/L) (p < 0.05). At admission,
IL-6 was detected in 50% of the ACS patients and 5% of the SA patients or control subjects,
while TNF was detected in 35% of the ACS and SA patients but only in 5% of control subjects.
Subsequently, IL-6 levels declined and were no longer detectable, while TNF levels increased
among ACS patients at all time periods tested when compared with other patients. The presence
of IL-1 and IL-10 were not detectable in the blood samples examined, and IFN could only be
detected in the ACS group. A significant correlation was observed between IL-6 and CRP
levels (r = 0.4; p < 0.01) in all groups. There were no correlations among any of the other
cytokines and CRP levels.
Conclusions: Our study demonstrates raised levels of TNF, IL6, IFN, and CRP in patients
with ACS and a positive correlation between IL6 and CRP but not with the other cytokines.
Keywords: cytokines, tumor necrosis factor-α, interleukin-6, C-reactive protein, coronary
artery disease
Introduction
Atherosclerosis can be considered an inflammatory disease as a number of ongoing
inflammatory responses and immune reactions occur in the vessel wall (Ross 1999).
Atherosclerotic lesions are filled with immune cells that coordinate and affect
inflammatory responses. In fact, the initial lesions of atherosclerosis consist of
macrophages and T cells, which both produce and secrete cytokines (Hansson et al
1997).
It is believed that the inflammatory responses related to atherosclerosis are, to a
slight degree, caused by local inflammation in atherosclerotic tissue. Known, locally
generated markers of inflammation are tumor necrosis factor-α (TNF) and interleukin-6
(IL-6) (Hansson et al 1997). Together, TNF and IL-1 stimulate the production of IL-6
by smooth muscle cells (Ng et al 1994). IL-6 gene transcripts are expressed in human
atheromatous lesions (Rus et al 1996), and IL-6 is the main hepatic stimulus for
C-reactive protein (CRP) production (Kulmatycki et al 2001).
Inflammation is also involved in the clinical manifestations of atherosclerosis
(Biasucci et al 1996; Libby and Ridker 1999). Increased plasma levels of
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proinflammatory cytokines, such as IL-1, IL-6, and IL-8,
have been reported in unstable but not in stable coronary
artery disease (CAD) (Biasucci et al 1996; Fernandes et al
2004). The pattern and magnitude of release of inflammatory
markers at the site of tissue injury is considered a critical
determinant of the severity and duration of the response
(Hansson et al 1997; Serrano Jr et al 1997; Ross 1999). In
contrast, IL-10 appears to have an antiinflammatory
(antiatherosclerotic) effect since it inhibits cytokine secretion
(Hansson 2001).
Several reports have suggested that plasma CRP can
predict increased risk of coronary heart disease (Danesh et
al 2000), and concentration of CRP has been directly
correlated with the presence and severity of coronary
atherosclerosis (Haverkate et al 1997). Plasma concentration
of CRP has been taken as an indication of overall
inflammatory activity within the body (Danesh et al 2000).
In addition, it has been suggested that CRP amplifies the
underlying cytokine signal in the disease process (Haverkate
et al 1997).
On the basis of the hypothesis that coronary athero-
sclerosis is associated with signs of inflammation, the
present study was undertaken to assess the changes over
time of the plasma levels of cytokines and CRP in patients
with stable and unstable CAD.
Methods
Study population
This study was approved by our institution’s committee on
human research. The informed consent to participate in the
study was obtained from all of the subjects. The groups in
the investigation included patients with acute coronary
syndromes (ACS; n = 20), stable angina (SA; n = 20), and
individuals without known cardiovascular disease (control;
n = 20). The groups were age- and sex-matched.
Definitions
An ACS was defined either as an unstable angina (group
IIIB of Braunwald classification) (Braunwald 1989) or as
an acute myocardial infarction without ST segment elevation,
which was diagnosed on the basis of the presence of chest
pain and typical ischemic electrocardiographic changes.
Stable angina was defined on the basis of the presence of
typical and stable chest pain during effort, a positive
treadmill exercise test, and obstructive coronary lesions as
determined by coronary angiography (> 75% stenosis). The
control group consisted of volunteers without ACS.
Protocol
Blood samples for cytokines and CRP were obtained from
an antecubital vein. In patients with ACS, blood samples
were obtained at admission.Venous blood taken on
admission or thereafter (at days 15 and 30) (Caligiuri et al
1998) were collected into a tube containing 0.5 mL of
sodium citrate (0.13 mol/L, pH 7.5). All blood samples were
immediately centrifuged at 3000 rpm for 10 minutes at room
temperature, and the aliquots of plasma were stored at
–80 
oC for enzymatic immunoassay (ELISA) assays.
Cytokine levels were measured using a commercially
available ELISA kit (R&D Systems Inc, Minneapolis, USA):
cytokines TNF, IL-1, IL-6, and interferon-γ (IFN); and IL-10,
with sensitivities of 3.0 pg/mL for IL-6, IFN, and IL-10;
and 0.5 pg/mL for IL-1 and TNF. The assays employed the
quantitative sandwich enzyme immunoassay technique.
To avoid variation within an assay, measurements were
performed in duplicate, simultaneously using the same
ELISA kit to avoid variation within assay, and in a blind
manner. Baseline plasma samples from each patient and
control subject were assayed for CRP with the use of latex-
enhanced immunonephelometric assays on a BN II analyzer
(Dade Behring, Newark, Del, USA). The range of detection
for CRP was 0.75–1100 mg/L.
Statistical analysis
Discrete variables are expressed as counts (number and
percentage) and were compared by chi-square or Fisher’s
exact test as appropriate. Continuous variables are expressed
as means ± SEM and compared using the Student t-test or
the Mann-Whitney test when the distribution was abnormal.
Continuous variables are also categorized according to the
presence or absence of detection in the diagnostic test. The
definiton of the cytokine being “present” is when it is above
the lower limit of the assay’s detection. Statistical
significance of changes of plasma cytokine levels over time
were evaluated by 1-way analysis of variance with repeated
measures and Duncan’s test (Shimomura et al 1998).
Spearman’s rank test was used for correlations. Probability
levels < 0.05 were considered statistically significant.
Results
The baseline characteristics of matched controls, patients
with ACS, and SA patients are shown in Table 1. There were
no marked differences among the three groups in the
following variables: age, gender, and the presence of
coronary risk factors (smoking status, hypertension, diabetesVascular Health and Risk Management 2005:1(3) 247
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mellitus, family history of premature CAD, and
hypercholesterolemia).There were no significant differences
between ACS and SA groups in medications being taken
(statins, angiotensin-converting enzyme inhibitors, and
aspirin) at the time of blood sampling.
On admission, CRP levels of (20.8 ± 8.8 mg/L) at
baseline in ACS patients were significantly (p < 0.05) higher
than SA patients (4.1 ± 0.8 mg/L) or control subjects
(5.1 ± 1.8 mg/L) (Table 2). A significant correlation was
observed between IL-6 and CRP levels (r = 0.4; p < 0.01) in
all groups. There were no correlations among other
cytokines and CRP levels.
IL-6 was detected in 50% of the ACS patients and 5%
of the SA patients and control subjects (Figure 1a). The
levels of IL-6 in ACS patients was 7.5 ± 3.9 pg/mL (Table 2).
TNF was detected in 35% of the ACS and SA patients, but
only in 5% of control subjects (Figure 1a). It was possible
to detect the presence of IFN in the ACS group but only in
10% of these patients (Figure 1a).
Table 1 Baseline clinical characteristics of controls and
patients with ischemic heart disease
ACS SA Control
(n = 20) (n = 20) (n = 20)
Age (years) 58.9 ± 12.4 57.0 ± 9.1 57.6 ± 6.4
Sex (male/female) 14/6 13/7 13/7
Risk factor
Hyperlipidemia 10 (50) 13 (65) 9 (45)
Diabetes 6 (30) 3 (15) 4 (20)
Hypertension 8 (40) 10 (50) 14(70)
Family history 7 (35) 7 (35) 8 (40)
Smokers 10 (50) 7 (35) 3 (15)
Serum total
cholesterol (mg/dL) 221.6 ± 13.8 198.3 ± 14.0 194.5 ± 12.2
Serum LDL
cholesterol (mg/dL) 153.2 ± 15.2 142.2 ± 14.1 137.1 ± 12.2
Angiography
Single-vesssel disease 6 (30) 10 (50) 0 (0)
Multivessel disease 9 (45) 7 (35) 0 (0)
NOTE: Values are expressed as means ± SEM or numbers (percentages). Thirteen
of 20 control subjects had undergone coronary angiography.
Abbreviations: ACS, acute coronary syndromes; SA, stable angina; LDL, low-
density lipoproteins.
Table 2 Baseline cytokines and C-reactive protein of controls
and patients with ischemic heart disease
ACS SA Control
(n = 20) (n = 20) (n = 20)
CRP (mg/L) 20.8 ± 8.8
a 4.1 ± 0.8 5.1 ± 1.8
IL-1 (pg/mL) nd nd nd
IL-6 (pg/mL) 7.5 ± 3.9 (22.2)b (9.1) b
IL-10 (pg/mL) nd nd nd
IFN (pg/mL) 304.1 ± 254.4 nd nd
TNF (pg/mL) 4.3 ± 0.9c 2.8 ± 0.9 1.2 ± 1.2
a p < 0.05.
b (one value, only).
c p > 0.05.
NOTE: Values are expressed as means ± SEM.
Abbreviations: ACS, acute coronary syndromes; SA, stable angina; CRP, C-reactive
protein; IL-1, interleukin-1α; nd, not detectable; IL-6, interleukin-6; IL-10,
interleukin-10; IFN, interferon-γ; TNF, tumor necrosis factor-α.
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Figure 1 Distribution of rates’ frequency of cytokines detection on admission
(baseline, a), at 15 days (b), and at 30 days (c) in patients with ACS, SA, and in
individuals without cardiovascular disease (Control). Abbreviations: ACS, acute
coronary syndromes; IFN, interferon; IL-6, interleukin-6; SA, stable angina; TNF,
tumor necrosis factor-α.
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On follow-up, at days 15 and 30, IL-6 was no longer
detectable in the ACS patients or in control subjects, while
it was still detectable in one patient in the SA group (Figures
1b, 1c). TNF could be detected in 35% and 40% of the ACS
patients, 30% and 20% of the SA patients and 15% and
15% of control subjects, at days 15 and 30, respectively
(Figures 1b, 1c).
ACS patients presented higher (though insignificantly
so) plasma TNF concentration than SA patients and control
individuals: 4.3 ± 0.9 vs 2.8 ± 0.9 vs 1.2 ± 1.2 pg/mL on
admission (Table 3), with this difference persisting up to the
30-day follow-up. Plasma levels of TNF were similar among
SA and control groups, and those of IFN for ACS group
were 304.1 ± 254.4, 830.0 ± 368.5, and 351.4 ± 43.0 pg/mL
on admission and at 15 and 30 days, respectively. The plasma
levels of IFN reached their peak at day 15 and then declined.
However, the peak level detected was not significantly
different to the level measured at admission or at 30 days
post-admission. The presence of IL-1 and IL-10 were not
detectable in the blood samples examined.
Discussion
This study shows that in humans, various clinical forms of
CAD affect the plasma levels of inflammatory cytokines
differently. However, no more than 50% of subjects at any
one point in time had elevated or detectable levels of
cytokine concentrations. Thus, these findings call into
question the clinical value of measuring cytokines as
inflammatory markers in patients with CAD. Although
several cytokines might be predictive of clinical disease,
the laboratory tests to assess inflammation are limited to
those that are detectable in clinical settings and that have
standardized, commercially available assays.
The evidence from the present study indicates that
baseline CRP, IL-6, and TNF increased in ACS patients as
compared with SA patients or control subjects. Our present
findings are in agreement with other reports (Maury and
Teppo 1989; Liuzzo et al 1998). A possible explanation for
the large variation (ie, SD) in the levels of CRP measurement
in ACS patients in this investigation could be a lack of tight
normal distribution within the population studied.
Other investigators have affirmed that IL-6 levels are
markedly elevated in patients with unstable angina, although
the cytokine was not detectable in all patients with this
condition (Biasucci et al 1996; Tashiro et al 1997). Thus,
our present findings support the view that IL-6 may be
involved in ACS to a greater extent than in other stable forms
of CAD, but that IL-6 levels are no longer detectable at 15
days following the acute phase of instability.
In contrast, it was possible to detect some TNF levels
after at least 30 days of the onset of ACS. Ridker et al (2000)
have reported that plasma concentration of TNF remains
elevated many months after myocardial infarction and that
very high levels are associated with an increased risk of
recurrent coronary events (Ridker et al 2000). The source
of persistently elevated levels of TNF is uncertain (Marx et
al 1997; Irwin et al 1999). Additional studies will be required
to determine the source of the TNF elevations observed in
these data.
In our study, IFN was detected only in patients with ACS
at baseline. Since IFN is produced by T-lymphocytes which,
among their functions inhibit collagen production by smooth
muscle cells (Amento et al 1991; Irwin et al 1999), IFN
could also have a fundamental role in the instabilization of
atherosclerotic plaques. Therefore, it is understandable that
IFN is only detectable in ACS patients, at admission, and
not in SA patients and control individuals.
We did not find IL-1α in the plasma of patients tested
and this is consistent with reports by other investigators
(Tashiro et al 1997; Smith et al 1999). On the other hand,
IL-1β plasma levels are elevated in patients with unstable
angina (Simon et al 2000). This could be explained by the
fact that IL-1β is secreted as a soluble protein and might be
more easily detected in the blood collected from the
peripheral circulation than IL-1α.
These prospective data indicate that baseline CRP
concentration could be a better marker for inflammation
than cytokines in patients with CAD. One potential
limitation of this study is that the control group included
individuals with coronary risk factors. We did, however,
confirm the absence of CAD through a normal coronary
angiography. Furthermore, plasma levels of cytokines might
have been below the detection levels of the assay used.
Table 3 Serial changes in plasma levels of tumor necrosis
factor-α (TNF) of controls and patients with ischemic heart
disease
Period
Groups Admission Day 15 Day 30 p
ACS (pg/mL) 4.3 ± 0.9 3.8 ± 0.9 4.1 ± 0.9 NS
SA (pg/mL) 2.8 ± 0.9 2.7 ± 0.8 3.8 ± 2.1 NS
C (pg/mL) 1.2 ± 1.2 2.7 ± 0.9 4.4 ± 1.6 NS
pN S N S N S
NOTE: Values are expressed as means ± SEM.
Abbreviations: ACS, acute coronary syndromes; C, control; NS, not significant
(p > 0.05); p, probability; SA, stable angina.Vascular Health and Risk Management 2005:1(3) 249
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Needless to say, a more sensitive assay system may have
revealed abnormal cytokine levels.
A comparison of the various studies reveals substantial
heterogeneity in the results that could be explained by
methodological differences. Clearly, the heterogeneity of
the present data could be related to the time of sampling,
the study design, or the exclusion criteria employed, which
is also a potential limitation of the study (Whiteside 1994).
Accurate biological levels of the cytokines are difficult
to obtain, since these mediators are involved in complex
molecular and cellular cascades and the only accessible
compartment is the circulation, in which such proteins have
short half-lives. Furthermore, assays for cytokines are
technically difficult and generally unreliable. By contrast,
immunoassays that cover the normal ranges as well as being
reliable, sensitive, and robust have been developed.
It is possible that investigators are less likely to submit
studies with negative results for publication; even if an
investigator chooses to submit a report with negative
findings, publication of such a report is less likely (Gibaldi
1993). Therefore, evaluation of only published material may
lead to a bias in favor of positive results.
The assays that measure markers of inflammation in
cardiovascular disease are becoming an important part of
the clinical laboratory repertoire. The appropriate type of
laboratory blood tests for the purpose of risk stratification
and therapeutic and clinical monitoring remains to be
established in patients at risk of coronary events. Current
evidence supports the use of CRP as the analyte of choice
(Pearson et al 2003). Although based on current findings, it
is evident that the variation in CRP measurements is quite
high, and it seems that Danesh et al (2004), analyzing data
from the Reykjavik Study, have suggested that CRP may be
not as good a predictor of future cardiac events as was
previously thought. Furthermore, our data indicates that the
measurement of cytokines as alternative analytes cannot be
recommended at this time and further research is needed.
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